Breaking News

Researchers vie for STAT Madness prize; health tech deals and events to watch

    

 

Daily Recap

'Skinny, greasy mice,' artificial cells, and tumor mapping: Researchers vie for STAT Madness championship

By Isabella Cueto

Hechler Photographers for STAT

Three finalists in the STAT Madness tournament presented their research before judges at the STAT Breakthrough Science Summit on Thursday.

Read More

STAT+: The health tech tracker for the second quarter: the decisive industry deals and events to watch

By Casey Ross and Katie Palmer

Adobe

Here's STAT's guide to the moves, trends, and deals to watch in the health tech industry as the second quarter begins.

Read More

Moving xenotransplantation research into human trials will require adjusting our expectations, researchers say

By Isabella Cueto

Hechler Photographers for STAT

Standard transplant success rates ignore the thousands who die of organ failure every year without being able to get a transplant.

Read More

STAT+: In the wake of Covid, a World Health Assembly proposal would bolster quality of clinical trials

By Ed Silverman

Molly Ferguson for STAT

Ahead of a World Health Assembly meeting, the U.K. is circulating a resolution that outlines goals to improve the quality of clinical trials.

Read More

Opinion: Narrowing the vaccine gap as boosters begin for people over 50

By Rebecca Weintraub and Benjy Renton and David C. Grabowski

Mario Tama/Getty Images

Among those over 50, 15% aren't fully vaccinated and 50% haven't received a booster. Protecting those at greatest risk requires more funding.

Read More

As research grows on primary care and serious mental illness, a glaring gap remains

By Theresa Gaffney

Adobe

Research shows people with serious mental illnesses struggle to access primary care. But relatively few studies focus on systemic solutions.

Read More

Opinion: Digital health is overlooking its biggest opportunity for disruption

By Sean Doolan

Adobe

Providers need digital health tools that improve workflows, help them to evaluate information, and give them more time with their patients.

Read More

STAT+: Mark Cuban's company is building a 'parallel supply chain' for prescription drugs

By Rachel Cohrs

Adobe

Mark Cuban’s generic drug company has had to grapple with which parts of the supply chain to develop themselves.

Read More

Friday, April 1, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments